Dyslipidemia Pharm - Cardio Exam 2

Dyslipidemia Pharm - Cardio Exam 2
4 main Statin benefit groups
1. Individuals with ASCVD
2. LDL-C > 190 mg/dL
3. DM aged 40-75 with LDL 70-189 w/o ASCVD
4. Individuals without ASCVD or DM with LDL 70-189 and 10 year risk
for ASCVD > 7.5%


low intensity statins drop LDL-C by how much
<30%


moderate intensity statins drop LDL-C by how much
30-50%


high intensity statins drop LDL-C by how much
> 50%


List the low intensity doses for statin therapy

Simvastatin 10mg

Pravastatin 10-20mg

Lovastatin 20 mg

Fluvastatin 20-40 mg


List the high intensity doses for statin therapy

Atorvastatin 40-80mg

Rosuvastatin 20-40mg

, What is the mainstay of treatment for hyperlipidemia?
Statin therapy

Decrease LDL by 18-63%

Increase HDL by 5-15%




MOA of Statins or [HMG CoA Reductase Inhibitors]
Interrupt the conversion of HMG-CoA to mevalonate, the rate-limiting
step in cholesterol biosynthesis




what are statins' role in therapy
drug of choice for lowering LDL

- lowers CV events at the same rate




how are statins metabolized? what does this mean for treatment?
hepatically metabolized - require LFT monitoring and holding for
elevations




AE of statins
- Headache

- Insomnia

- Increased LFTs/CK